The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon

Boult Wade Tennant LLP

CPC 4 CAPITAL PARK, CAMBRIDGE ROAD, CAMBRIDGE, CB21 5XE, ENGLAND
Tel:
Work 01223 883000
Fax:
Fax 01223 883001
Email:
Web:
www.boult.com
Cambridge, London, Madrid, Munich, Munich, Oxford and 1 more

James Legg

Tel:
Work +44 (0)1223 883000
Email:
Boult Wade Tennant LLP

Work Department

James, is a Chartered Patent Attorney and European Patent Attorney in the Biotechnology and Life Sciences Group.

Position

Partner

Career

James has experience in advising on a wide range of intellectual property and commercial matters affecting both large and small biotech and life science clients. He specialises in preparing and prosecuting UK, European and PCT patent applications, and in representing clients in European opposition and appeal proceedings. He has also advised clients involved in multi-jurisdictional patent litigation.

James has particular expertise in handling patent and technology matters relating to biological therapeutics and molecular biology, acting in matters regarding antibody therapeutics and vaccines, diagnostic assays, genetic analysis, genetic engineering and gene silencing and stem cell technology. He has worked with clients from a diverse range of industries including: pharmaceuticals, biologics, biomedical, diagnostics, nutrition, and consumer goods companies.

Prior to joining the patent profession, James worked as a consultant in the innovation and technology management group at Sagentia Ltd, and was also part of a research and development team for Procter & Gamble, Brussels

Member

  • CIPA
  • EPI

Education

  • Chartered UK Patent Attorney
  • European Patent Attorney
  • PhD Molecular Biology, University of Cambridge
  • MA (Cantab) Natural Sciences, University of Cambridge


London: TMT (technology, media and telecoms)

PATMA: Patent attorneys

Within: PATMA: Patent attorneys

Boult Wade Tennant has 'unparalleled professionalism in UK and European IP matters' with 'fast response times', 'clear and concise advice', and 'a team of individuals with valuable expertise in various areas of technology'. Nick McLeish leads the high tech and electrical group, and alongside Tony Pluckrose  advised Boeing on its European patent portfolio. Nina White heads the biotechnology and life science group, and alongside Joanna Peak represented Hoffman-La Roche in opposing Centre National de la Recherche Scientifique's patent, which treats cognitive impairments for people with down syndrome. Matthew Spencer and James Legg defended Adaptive Biotechnologies from three opposing parties of its technology, which protects against immune profiling. Nick Widdowson is also a key figure and assisted Intelligent Fingerprinting with the development of its patent portfolio. Daniel Weston and Neil Thomson worked with Generale Biscuit on its patent portfolio. James Short assisted Gravity Industries with building its patent portfolio. Other noteworthy names include Alex Frost and Simon Kahn, who both acted for Hamamatsu Photonics against Leica Microsystems, which opposed the client's telemicroscopy patent. Adrian Hayes, Michelle Pratt and Jonathan Palmer are also recommended.

[back to top]


Back to index

Legal Developments by:
Boult Wade Tennant LLP

  • Boult Wade Tennant ranked top tier for Trade Mark in MIP‚Äôs IP Stars Handbook

    We are delighted to announce that Managing Intellectual Property (MIP) has ranked our trade mark practice in the top tier of its 2016 annual survey. MIP’s IP Stars rankings are based on extensive research among thousands of intellectual property practitioners from around the globe, creating one of the most comprehensive and authoritative surveys of the IP legal market. It covers 80 countries and identifies the best patent, trade mark and copyright firms and practitioners in the world.
    - Boult Wade Tennant

Legal Developments worldwide

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to
  • Foyen has advised Mandalay Resources in 32 Million USD share issue

    Foyen has advised Canadian mining company Mandalay Resources Corporation inits marketed public offering of shares (subscription rights) on the Toronto stock exchange for aggregate gross proceeds of 43 million CAD (32 MUSD).Mandalay is the 100 % owner of the Bjorkdal gold mine in northern Sweden and the transaction has required legal opinions regarding all companies and permits in the Swedish business operation.
  • Foyen recruits lawyer from the Court of Appeal

    Foyen Advokatfirma has recruited lawyer Erika Stjärnström from the Göta Court of Appeal. Erika has joined the law firm's Construction business sector, writes Foyen in a press release .
  • UNEXPLAINED WEALTH ORDERS: THEIR POTENTIAL AND THE RIGHT WAY TO RESPOND IF FACED WITH ONE

    Aziz Rahman considers why we may see an increase inunexplained wealth orders (UWO’s) and the implications for law enforcement and individuals.
  • AVELLUM advises on IBRD-supported financing for Ukraine

    AVELLUM acted as the Ukrainian legal counsel to the Ministry of Finance of Ukraine in connection with two syndicated EUR-denominated facilities arranged by Deutsche Bank in December 2018 and March 2019 for the total amount equivalent to approximately USD1 billion.
  • AVELLUM advises EBRD and BSTDB on financing of one of largest solar projects in Ukraine

    AVELLUM acted as the Ukrainian legal counsel to the European Bank for Reconstruction and Development (‚ÄúEBRD ‚ÄĚ) and the Black Sea Trade and Development Bank (" BSTDB ") in connection with senior secured loans in the total amount of up to EUR36.3 million to Rengy Bioenergo LLC (‚ÄúLoans ‚ÄĚ).
  • Gulbenkian Andonain discuss NEW Tier 1 Start-Up Visa and the NEW Tier 1 Innovator Visa

    The document entitled "Statement of Changes to Immigration Rules" which was released by the House of Commons on the 7th March 2019, outlined and advised us on a number of changes that will come into place that will affect the Tier 1 Investor Visa amongst other visa programmes and schemes. The latest article on our website discusses both of these new UK business visa routes. Our immigration lawyers London are already up to date on all of the required information for both the NEW Tier 1 Start-Up Visa and the NEW Tier 1 Innovator Visa .
  • Upcoming Changes to the UK Tier 1 Investor Visa

    According to the new document from the House of Commons on March 7th 2019 titled ‚ÄúStatement of Changes to Immigration Rules‚ÄĚ, a number of changes will come into place that affecting the Tier 1 UK Investor Visa programme amongst other visa programmes and schemes. Read about them in our latest¬† article .¬†
  • Illegal advertisement of effect of a medicinal product

    It is illegal to advertise a specific effect attributed to a medicinal product if said effect is based merely on laboratory tests and has not been demonstrated in relation to humans.
  • Brexit and non-EU Immigration

    There is no doubt that the UK has to date benefited immensely from visa-free EU immigration to the extent that visa conditions and caps on non-EU migrant have undermined and overshadowed the ability of this group to play a prominent role in British industry and commerce and in its expanding and overburdened NHS service. It is the view of  Gulbenkian Andonian  however, that after  Brexit, there should be a noticeable change in those skilled non-EU migrants contributing to British society in a meaningful way. 
  • Gulbenkian Andonian Solicitors discuss Post Brexit scenarios - EU Nationals and Salient Immigration

    From 1 January 2021 everyone except for British and Irish citizens will be subject to immigration control in the UK.   Gulbenkian Andonian solicitors has already published an article on this topic of post- Brexit immigration and has discussed the case of EU nationals and family members after Brexit, you can find that article here as one of many in our blog .